Janet Hsueh

Janet Hsueh is an associate in the firm’s Business Law department and a member of its Technology and Life Sciences groups. Janet represents clients across the life sciences and technology industries, including private equity funds, investment banks, and public and private companies.

Her work extends to every stage of the corporate life cycle, from financing through successful initial public offering or acquisition, with a focus on public and private capital markets transactions such as IPOs, follow-on offerings and private placements of equity and debt securities. She also counsels clients on a wide array of corporate matters, including public and private securities offerings, mergers and acquisitions, securities law compliance, corporate governance, and strategic transactions.

Capital Markets and Other Significant Transactions

• Talaris Therapeutics in connection with its $150 million initial public offering, its “at-the-market” program and its reverse merger with Tourmaline Bio
• argenx in connection with multiple follow-on offerings of more than $1.7 billion
• Checkmate Pharmaceuticals in connection with its “at-the-market” program and its acquisition by Regeneron Pharmaceuticals for $250 million
• Calliditas Therapeutics in connection with its $96 million U.S. initial public offering, its $37 million follow-on offering and its $75 million “at-the-market” program
• Nuvalent in connection with its $190 million initial public offering
• Olink in connection with its $246 million initial public offering
• Fusion Pharmaceuticals in connection with multiple PIPEs of more than $80 million and its $200 million “at-the-market” program
• Black Diamond Therapeutics in connection with its $75 million follow-on offering
• Hansa Biopharma in connection with its $40 million global private offering
• Trillium Therapeutics in connection with multiple follow-on offerings of more than $174 million
• The underwriters of NAPCO Security Technologies’ $74 million follow-on offering
• The initial purchaser of Zynex’s $60 million notes offering
• Tome Biosciences in connection with its $100 million Series B financing

Mergers and Acquisitions

• Magenta Therapeutics in its reverse merger with Dianthus Therapeutics
• Alvarium Investments in its business combination with Cartesian Growth Corporation, Tiedemann Advisors and TIG Advisors
• Frazier Lifesciences Acquisition Corporation in its business combination with NewAmsterdam Pharma
• Consonance-HFW Acquisition Corporation in its business combination with Surrozen
• Cerveau Technologies in its sale to Lantheus Medical Imaging
• ZOLL Medical Corporation in its acquisition of Respicardia

Prior to joining Goodwin, Janet was an associate in the Corporate group at Cadwalader, Wickersham & Taft LLP in New York.